Boston-based PureTech Health plc is a biotherapeutics company that is focused on discovering, developing and commercializing medicines aimed at treating a number of diseases including inflammatory, fibrotic, immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases. The clinical-stage company has developed a range of oral therapies that are based on consortia of bacteria that have been isolated from the human microbiome. They also offer hematopoietic stem cell-based therapies for patients with blood cancer, as well as a voice-based technology platform that can detect voice changes linked to certain health conditions, and a pioneering technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, PureTech Health plc is developing LYT-100 to treat lymphedema, a synthetic lymphatic targeting chemistry platform called Glyph, the Orasome technology to enable the oral administration of macromolecule therapeutic payloads, and the Alivio technology platform for inflammation-targeted disease immunomodulation. The company’s collaborations and license agreements include Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd. PureTech Health plc was incorporated in 2015 and has emerged as a leading innovator in the field of biotherapeutics for a wide range of diseases.
PureTech Health's ticker is PRTC
The company's shares trade on the LSE stock exchange
They are based in Boston, Massachusetts
There are 51-200 employees working at PureTech Health
It is puretechhealth.com
PureTech Health is in the Healthcare sector
PureTech Health is in the Biotechnology industry
The following five companies are PureTech Health's industry peers: